Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Ocular Surface Disease > Is MMP-9 a viable biomarker for dry eye disease diagnosis?
  • Ocular Surface Disease

Is MMP-9 a viable biomarker for dry eye disease diagnosis?

Ophthalmology 360

Despite initial hopes and the known role of matrix metalloprotein 9 (MMP-9) as an inflammatory mediator contributing to ocular surface damage in DED, a new study did not find a significant correlation between MMP-9 levels and dry eye disease (DED) severity.

The study also noted gender differences in MMP-9 positivity, with more males testing positive than females, and identified associations with postmenopausal status and tear interferon-gamma levels.

The study, involving 211 participants, utilized MMP-9 point-of-care testing at screening and 3 months into the research. The researchers analyzed associations between MMP-9 results and various factors, including keratography testing, clinical examinations, and the Ocular Surface Disease Index.

The results indicated a significant gender difference among MMP-9 positive subjects, with 70% of males testing positive compared to 51% of females (P = 0.01). Postmenopausal status (P = 0.02) and tear interferon-gamma levels at baseline (P = 0.047) were also found to be significantly related to MMP-9 positivity. However, no significant associations were observed between MMP-9 levels and other cytokines or HLA-DR status.

Contrary to expectations, the study did not find any significance between baseline MMP-9 levels and both baseline and 3-month DED measures. Furthermore, no notable correlation was identified between changes in MMP-9 status and changes in DED symptoms over the course of the study.

Reference
Reidy C, et al. Analysis of the Use of MMP-9 as a Biomarker for DED. Poster Presented at: AAO 2023.

Share

Related Content

  • Ocular Surface Disease

Symptomatic MGD shows distinct age-related clinical patterns

  • Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

  • Dry Eye

Spotlight on LACRIFILL®

  • Glaucoma

Review finds low adverse event rates for glaucoma stents

  • Retina

Switching to aflibercept 8 mg extends treatment intervals in suboptimal nARMD responders

  • Conference Roundup

Cryopreserved amniotic membrane significantly improves ocular surface integrity in patients with severe keratoconjunctivitis sicca and neurotrophic keratopathy

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon